Weight loss drug combo trial pulled before it even started
NCT ID NCT05209984
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned phase 3 study to test a new combination of two drugs, sibutramine and topiramate, for weight loss in overweight and obese adults. The study aimed to see if the combination worked better than either drug alone or a placebo. However, the trial was withdrawn before enrolling any participants, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sibutramine and topiramate combination
What this could lead to
If successful, this could provide a new weight-loss medication option for adults who are overweight or obese.
What could go wrong
The trial was withdrawn before any participants were enrolled, so no results are available. Sibutramine has known safety concerns, including cardiovascular risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eurofarma Laboratórios S.A
São Paulo, São Paulo, 06696-000, Brazil
-
HC-FMUSP
São Paulo, São Paulo, Brazil